Description: Time to clinical benefit was assessed. The x-axis represents time from randomization, and the y-axis represents the degree of benefit at that time, as measured by the hazard ratio shown in blue. The vertical black line marks the day that the treatment benefit of sotagliflozin reached and maintained statistical significance. Despite the SCORED trial enrolling stable patients, by just 3 months, there was already a significant decrease in heart attacks and strokes – a very early benefit that is generally not seen with medications used in non-acute settings.
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.
Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor. It blocks the function of two proteins, known as SGLT1 and SGLT2, which move glucose and sodium across cell membranes and help control blood sugar levels. Other SGLT2 inhibitors do not as significantly block SGLT1.
The study, published February 14 in The Lancet Diabetes & Endocrinology, is the first to show that an SGLT inhibitor has these unique cardiovascular benefits. The results mean that sotagliflozin could become more widely used to reduce the risk of deadly cardiovascular events globally.